Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $39,319.38 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Conor Kilroy sold 7,162 shares of the company’s stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the sale, the insider now directly owns 179,313 shares in the company, valued at $984,428.37. This represents a 3.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Aura Biosciences Stock Performance

Shares of AURA opened at $5.36 on Friday. The company has a market cap of $269.21 million, a price-to-earnings ratio of -3.10 and a beta of 0.43. The firm has a fifty day moving average of $6.71 and a 200-day moving average of $8.16. Aura Biosciences, Inc. has a 1 year low of $4.84 and a 1 year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). Analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AURA. Charles Schwab Investment Management Inc. lifted its holdings in Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after purchasing an additional 3,612 shares during the period. Geode Capital Management LLC raised its position in shares of Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after buying an additional 3,972 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Aura Biosciences by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after acquiring an additional 5,930 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Aura Biosciences in the fourth quarter valued at approximately $50,000. Finally, Bank of America Corp DE boosted its holdings in shares of Aura Biosciences by 20.5% in the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock valued at $422,000 after acquiring an additional 8,709 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Wall Street Analyst Weigh In

AURA has been the topic of several research analyst reports. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Citigroup reaffirmed an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th. JMP Securities set a $19.00 price target on Aura Biosciences in a research report on Wednesday, March 26th. Finally, HC Wainwright set a $25.00 price objective on shares of Aura Biosciences in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $22.75.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.